« Back
Home /
Epirubicin (hydrochloride)

Epirubicin (hydrochloride)

Item no.	HY-13624A-10mM
Manufacturer	MedChem Express
CASRN	56390-09-1
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Breast Cancer Brain Cancer Bone Cancer
Type	Inhibitors
Specific against	other
Purity	99.16
Citations	[1]Cersosimo RJ, et al. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425-39.\|[2]Ozkan, A., et al. Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol, 2004. 56(4): p. 435-44.\|[3]Bonadonna, G., et al. Drugs ten years later: epirubicin. Ann Oncol, 1993. 4(5): p. 359-69.\|[4]Asanuma, F., et al. Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27. Folia Microbiol (Praha), 1998. 43(5): p. 473-4.\|[5]Kashima H, et al. Epirubicin, Identified Using a Novel Luciferase Reporter Assay for Foxp3 Inhibitors, Inhibits Regulatory T Cell Activity. PLoS One. 2016 Jun 10;11(6):e0156643. Anal Chem. 2022 Oct 4;94(39):13623-13630.\|bioRxiv. 2023 Jan 13.\|Br J Cancer. 2024 Aug 22.\|Breast Cancer. 2024 Dec 20:16:993-1004.\|Cancer Cell Int. 2024 Dec 27;24(1):433.\|Cancer Res Treat. 2023 Jun 12.\|Cell Death Discov. 2024 Jul 24;10(1):337.\|Cell Mol Immunol. 2023 Jan;20(1):51-64.\|Eur J Pharm Sci. 2024 Jul 21:106860.\|Int J Cancer. 2024 Jul 15;155(2):324-338.\|Int J Pharm. 2024 Aug 26:664:124622.\|Interdiscip Med. 2025 Feb 24.\|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.\|Mol Cell. 2022 Feb 17;S1097-2765(22)00085-5.\|Research Square Preprint. 2021 Nov.\|Asia Pac J Clin Oncol. 2022 Dec 4.\|bioRxiv. 2023 Apr 17.\|Cell Prolif. 2021 Apr 1;e13038.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Genome Med. 2024 Jan 12;16(1):11.\|Genomics. 2021 Nov 26;S0888-7543(21)00410-9.\|Int J Mol Sci. 2023, 24(1), 343.\|J Biomed Inform. 2023 May 15;104383.\|Mol Cancer. 2024 Jan 10;23(1):12.\|Mol Pharm. 2019 Aug 5;16(8):3452-3459. \|Oncol Lett. 2020 Apr. \|Research Square Preprint. 2020 May.\|Yonsei Med J. 2019 Sep;60(9):832-841.
Smiles	O=C(C1=C2C(O)=C3[C@@H](O[C@@]4([H])C[C@H](N)[C@@H](O)[C@H](C)O4)C[C@@](C(CO)=O)(O)CC3=C1O)C5=CC=CC(OC)=C5C2=O.Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	4'-Epidoxorubicin (hydrochloride)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Antibiotic; Apoptosis; DNA/RNA Synthesis; Topoisomerase
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture and light)
Molecular Weight	579.98
Product Description	Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase[1]. Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity[2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 25 mg/mL (ultrasonic)\|H2O: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Apoptosis; Cell Cycle/DNA Damage
Isoform	Topoisomerase
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13624A-10mM-safety-datasheet.pdf